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Abstract
Although current anti-cancer protocols are reasonably effective, treatment-associated long-
term side effects, induced by lack of specificity of the anti-cancer procedures, remain a chal-
lenging problem in pediatric oncology. TAT-RasGAP317-326 is a RasGAP-derived cell-
permeable peptide that acts as a sensitizer to various anti-cancer treatments in adult tumor
cells. In the present study, we assessed the effect of TAT-RasGAP317-326 in several childhood
cancer cell lines. The RasGAP-derived peptide-induced cell death was analyzed in several
neuroblastoma, Ewing sarcoma and leukemia cell lines (as well as in normal lymphocytes).
Cell death was evaluated using flow cytometry methods in the absence or in the presence of
the peptide in combination with various genotoxins used in the clinics (4-hydroperoxycyclo-
phosphamide, etoposide, vincristine and doxorubicin). All tested pediatric tumors, in re-
sponse to at least one genotoxin, were sensitized by TAT-RasGAP317-326. The RasGAP-
derived peptide did not increase cell death of normal lymphocytes, alone or in combination
with the majority of the tested chemotherapies. Consequently, TAT-RasGAP317-326 may ben-
efit children with tumors by increasing the efficacy of anti-cancer therapies notably by allowing
reductions in anti-cancer drug dosage and the associated drug-induced side effects.
Introduction
Cancer represents the second cause of death in children after accidents in industrialized coun-
tries [1, 2]. Our understanding of childhood cancers has benefited from significant advances
over the four last decades. Standard treatments to cure pediatric tumor include surgery, radia-
tion therapy and intensive multi-agent chemotherapy such as etoposide, vincristine, doxorubi-
cin, and cyclophosphamide [3].
In developed countries, eighty percent of children who are diagnosed with cancer are ex-
pected to survive within 5 years following the treatment. However, most of them will suffer
from chronic diseases by 40 years of age [4]. Extended surveillance of pediatric cancer survivors
shows a high risk for life-threatening late effects from second malignancies, cardiac conditions
and pulmonary diseases [5, 6]. The risk of early mortality is mostly determined by treatment-
specific factors such as the cumulative dose of chemotherapy [7]. Therefore, treatment-
associated long-term side effects induced by damage to non-tumor cells are a challenging
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problem and remain largely unresolved. As children are by definition long-term survivors,
there is a strong need to develop low-toxicity, better targeted and efficient new therapeutic
strategies for all types of childhood cancers [8]. Strategies to circumvent such obstacles include
the improvement of anti-cancer drug sensitivity and specificity toward cancer cells [9–11].
In this context, we previously reported that a cell-permeable peptide derived from the p120
RasGAP protein, called TAT-RasGAP317-326, is a tumor-sensitizer to various anti-cancer drugs.
Indeed, although it does not show any toxicity toward cells on its own, it efficiently and specifi-
cally sensitizes adult tumor cells in vitro and in vivo to various anti-cancer therapies, including
chemotherapy [12,13], and photodynamic therapy [14]. Importantly, it displays specificity to
cancer cells as it does not sensitize non-tumor cells to genotoxin-induced apoptosis [12, 14].
TAT-RasGAP317-326 appears to have additional anti-cancer activities than tumor cell sensitiza-
tion as it has been recently demonstrated that this peptide can hamper cell migration and inva-
sion in vitro [15, 16] and that this activity can inhibit the metastatization process in vivo [17].
This indicates that the RasGAP-derived peptide has the ability to act as an anti-metastatic com-
pound on top of its tumor sensitization effects. Recently, it has been shown that the anti-cancer
properties of TAT-RasGAP317-326 are dependent on two tryptophan residues at position 317
and 319 [16]. However, the mode of action of TAT-RasGAP317-326 is not fully characterized. It
has been previously shown that this peptide does not favor the death of tumor cells by modu-
lating Ras activity, MAPK signaling pathways, NF-κB transcriptional activity, Akt protein lev-
els and phosphorylation status [18, 19]. Moreover, the Bcl-2 family members, which regulate
mitochondrial-dependent cell death, were shown to be individually dispensable for the sensitiz-
ing activity of the peptide [20].
The effect of this peptide in childhood cancer is however not known. The molecular biology
of pediatric tumors is distinct from cancers in adults in many ways. As the genesis of most
childhood cancers seems to come from disruptions of normal early development, they accumu-
late fewer mutations than adult tumors. On the other hand, it appears that development of pe-
diatric tumors rely heavily on epigenetic modifications [21–23]. In the present study, we have
therefore investigated whether TAT-RasGAP317-326 was able to render childhood tumors more
sensitive to clinically relevant anti-tumor drugs.
Methods
Cell lines and culture cells
The CCRF-CEM [24], THP-1 [25] and A673 [26] cell lines were obtained from the American
Type Culture Collection (ATCC) (references CRL-8436, TIB-202, CRL-1598 respectively). The
LAN-1 [27] and M-07e [28] cell lines were obtained from the Leibniz Institute DSMZ-German
Collection of Microorganisms and Cell Cultures (references ACC655, ACC104 respectively).
The EW-11 [29], TC252 [30] and NB1-derived [31] cell lines were described earlier. All cell
lines were cultured in 5% CO2 at 37°C. The neuroblastoma cell lines (LAN-1, NB1-FBS,
NB1-FBS-Re) and the EW-11 Ewing sarcoma cell line were grown in Dulbecco’s modified
Eagle Medium (DMEM) (Gibco, Paisley, UK) containing 10% fetal bovine serum (FBS)
(Gibco). The NB1-NBM neuroblastoma primary tumor cells were maintained in neural basic
medium made of DMEM/F12 (Gibco) supplemented with 2% B27 serum-free supplement
(Invitrogen, Carlsbad, CA), 20 ng/ml human recombinant basic fibroblast growth factor
(bFGF) (Peprotech), and 20 ng/ml human recombinant epidermal growth factor (EGF)
(Peprotech). The CCRF-CEM and THP-1 acute leukemia cell lines, and the A673 and TC252
Ewing sarcoma cells, were cultured in RPMI 1640 (Gibco) containing 10% FBS. M07e, an acute
myeloid leukemia cell line, was maintained in Minimum Essential Medium alpha (MEMα)
(Gibco) supplemented with 10% FBS and 5 ng/ml recombinant human granulocyte
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macrophage colony-stimulating factor (GM-CSF) (Peprotech). Human peripheral blood lym-
phocytes (PBLs) were isolated by density centrifugation over a Ficoll-Paque gradient (Lympho-
prep; Stemcell Technologies) from buffy coats of healthy human donors, obtained from the
state of Vaud blood transfusion service. The donors gave written consent for potential use of
their blood for medical research. PBLs were cultured in RPMI 1640 (Gibco) supplemented
with 8% of pooled human serum and supplemented with 100 U/ml recombinant human inter-
leukin-2 (Proleukin, Roche Pharma AG).
Chemicals
The drugs used were vincristine (Sigma-Aldrich, St Louis, USA), etoposide (Sigma-Aldrich),
4-hydroperoxycyclophosphamide (4-HC) (Niomech, Bielefeld, Germany) and doxorubicin
(Pfizer AG, Zurich, Switzerland). The staining used to perform flow cytometry were 7-ami-
noactinomycin D (7-AAD) and Annexin V-FITC (Annexin V-FITC/7-AAD kit, Beckman
Coulter, Miami, USA).
Peptide synthesis
TAT-RasGAP317-326 (GRKKRRQRRRGGWMWVTNLRTD), TAT48-57 (from now on referred to as
TAT) (GRKKRRQRRR), TAT-Scrambled (GRKKRRQRRRGGWLDMTTVNRW) and TAT-Mutated
(GRKKRRQRRRGGAMWVTNLRTD) were synthesized at the Department of Biochemistry, Uni-
versity of Lausanne, Switzerland as described previously [12].
Cytotoxic assay
For cells growing in suspension (THP-1, M07e, CCRF-CEM, and lymphocytes), three hundred
thousand cells were seeded in 6-well plates and directly treated with the indicated doses of
4-HC, etoposide, vincristine, or doxorubicin in the presence or in the absence of 10 μM
TAT-RasGAP317-326, TAT, TAT-Scrambled or TAT-Mutated. For adherent cell lines
(NB1-NBM, NB1-FBS, NB1-FBS-Re, LAN-1, EW-11, TC252, and A673), two hundred thou-
sand cells were allowed to adhere for 48 hours in 6-well plates and were then treated like cells
growing in suspension. Twenty-four hours after drug incubation, cells were subjected to flow
cytometry to evaluate cell death. Briefly, adherent cell lines were detached by trypsin-EDTA
(Gibco) and single-cell suspensions were processed and stained with 1 μg/ml 7-AAD and 50
ng/ml Annexin V-FITC in 500 μl binding buffer. A minimum of ten thousand cells were ana-
lyzed. The 7-AAD dye-derived signal could not be used when cells were treated with doxorubi-
cin because 7-AAD and doxorubicin have similar fluorescent properties (7-AAD emission
wavelength: 525 nm; doxorubicin emission wavelength: 530 nm [32]).
Statistical analysis
Unless otherwise mentioned, all experiments were derived from three or more independent ex-
periments. The results were expressed as mean ± 95% confidence intervals. Significance was as-
sessed using t-tests performed with Microsoft Excel 2010 followed by Bonferroni corrections
(i.e. differences were considered significant when p values< 0.05/n, where n is the number of
comparisons made). Asterisks represent statistically significant differences. In the last figure,
significance was assessed by one-way ANOVAs followed by Bonferroni (Dunn) t post-hoc
tests using the SAS 9.2 software (SAS Institute Inc., Cary, NC, USA).
TAT-RasGAP317-326 in Pediatric Tumors
PLOS ONE | DOI:10.1371/journal.pone.0120487 March 31, 2015 3 / 16
Results
In this study, three types of childhood cancers were analyzed: neuroblastoma, leukemia, and
Ewing sarcoma. Among childhood malignancies, neuroblastoma is the most frequent extracra-
nial solid cancer. Deaths resulting from neuroblastoma account for 15% of all tumor related
death in children [33]. Multidrug resistance, acquired during exposure to chemotherapies,
plays a major role in this poor outcome [34, 35]. Leukemia is the most common childhood can-
cer type and represents one third of all pediatric tumors [36]. Although less prevalent than leu-
kemia, Ewing sarcoma is an aggressive cancer with a poor prognosis and a high rate of relapse
with metastatic disease [37]. The drugs employed here are all used in the clinics. Their proper-
ties are presented in Table 1.
TAT-RasGAP317-326 sensitizes acute lymphoblastic and myeloid
leukemia cells to various chemotherapeutic agents without showing any
effect toward tumor cells by itself
To investigate the sensitization effect of TAT-RasGAP317-326 in leukemia cells, three different
cell lines were subjected to increasing concentrations of cytostatic agents in the absence or in
the presence of 10 μM TAT-RasGAP317-326. Etoposide, vincristine, doxorubicin, and 4-hydro-
peroxycyclophosphamide (4-HC), the active form of cyclophosphamide, were the drugs used
here and are each currently employed in the clinic. Cell death was assessed using 7-AAD that
labels dead cells that have permeabilized plasma membrane and with Annexin V that binds to
phosphatidylserine exposed on dead cells. Some of the anti-cancer drugs used here induced a
concomitant appearance of the 7-AAD and Annexin V signals (Fig 1A shows the representa-
tive case of 4-HC). In other words, as soon as a cell became Annexin V-positive it also picked
up the 7-AAD dye. Hence, in our hands, anti-cancer drugs such as 4-HC induced a necrosis-
like type of death. In the next figures, the 7-AAD data are reported as we found them to be as-
sociated with a lower variance than those obtained with Annexin V staining (Fig 1B). The only
exception was when doxorubicin was used. Indeed, this dye fluoresces at similar wavelengths
as 7-ADD. In this case therefore, the Annexin V data are presented. These experiments re-
vealed that TAT-RasGAP317-326 significantly sensitizes leukemia cells to almost all tested drugs
(Fig 2A). However, in some conditions (for example when THP-1 cells are treated with vincris-
tine) tumor cells did not respond well to TAT-RasGAP317-326. A limited sensitization effect of
the RasGAP-derived peptide is not necessarily a consequence of intrinsic resistance to a drug
as the CCRF-CEM cell line, which is vincristine-resistant, was efficiently sensitized by
TAT-RasGAP317-326. This point is of particular clinical relevance as it indicates that TAT-Ras-
GAP317-326 can exert a sensitization effect in chemo-resistant cells.
Table 1. Mechanism of action and clinical use of cyclophosphamide, doxorubicin, etoposide and vincristine.
Drugs Class Mechanism of action Clinical use
Cyclophosphamide Alkylating agent Interstrand DNA crosslinker NB, ES, ALL, AML
Doxorubicin Antracycline DNA intercalation and inhibition of the progression of topoisomerase II enzymes NB, ES, ALL, AML
Etoposide Topoisomerase inhibitor Single or double strand breaks by trapping topoisomerase II enzymes on DNA NB, ES, AML
Vincristine Mitotic inhibitor Inhibition of assembly of microtubule structures NB, ES, ALL, AML
Only the tumor types that were analyzed in this study are mentioned here. The listing was based on the protocols of the Children’s Oncology Group and
the International Society of the Pediatric Oncology (EURO-E.W.I.N.G. 99; AALL0232; HR-NBL-1.5/SIOPEN). NB, neuroblastoma; ES, Ewing sarcoma;
ALL, acute lymphoblastic leukemia; AML: acute myeloid leukemia.
doi:10.1371/journal.pone.0120487.t001
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TAT-RasGAP317-326 by itself did not induce cell death in the tested leukemia cell lines, even
at a two-fold higher concentration (20 μM) than the one used to induce a sensitization effect
(10 μM) (Fig 2A).
TAT-RasGAP317-326 does not display toxicity toward non-tumor
lymphocytes from healthy subjects.
It was shown previously using non-tumor immortalized human keratinocytes (HaCaT) and
umbilical vascular endothelium (HUV-EC-C) cells that TAT-RasGAP317-326, in combination
Fig 1. Necrosis-like death induced by 4-HC in CCRF-CEM cells. A. Three hundred thousand CCRF-CEM cells were seeded in 6-well plates and directly
treated with 50 μM 4-HC. Cell death was evaluated after several time points (0, 3, 6, 12 and 24 hours) using 7-AAD and Annexin V-FITC staining. B.
CCRF-CEM cells were seeded in 6-well plates and directly treated with the indicated doses of 4-HC, etoposide or vincristine in the presence or in the
absence of 10 μM TAT-RasGAP317-326. After 24 hours of drug incubation, 7-AAD and Annexin V-FITC staining was performed to evaluate cell death. 4-HC,
4-hydroperoxycyclophosphamide.
doi:10.1371/journal.pone.0120487.g001
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with various genotoxins, did not sensitize non-tumor cells [12]. In the present study, we used
isolated lymphocytes from whole blood of healthy patients to investigate the selectivity of the
RasGAP-derived peptide toward cancer cells. We used the same dosages of chemotherapeutic
agents to treat healthy lymphocytes as those used to treat the CCRF-CEM T-acute
Fig 2. The effect of TAT-RasGAP317-326 as a chemosensitizer of leukemia cells and non-tumor lymphocytes. A. Two acute myeloid leukemia cell lines
(THP-1 and M-07e) and one T acute lymphoblastic leukemia cell line (CCRF-CEM) were seeded in 6-well plates and directly treated with 4-HC, etoposide,
vincristine or doxorubicin at the indicated concentrations in the presence or in the absence of 10 μM TAT-RasGAP317-326. After 24 hours of drug incubation,
7-AAD or Annexin V-FITC staining was performed to evaluate cell death (last four columns). Alternatively (first column), the cells were treated with increasing
concentrations of TAT or TAT-RasGAP317-326 alone. After 24 hours, the evaluation of cell death was carried out using 7-AAD staining.B. Isolated
lymphocytes from three distinct healthy subjects were treated as described in Fig. 2A. The dosages of chemotherapeutic agents used to treat the healthy
lymphocytes from the three subjects are similar to those used to treat the T-ALL CCRF-CEM cells. Note that the graphs are derived from single experiments
where lymphocytes are immediately used after their isolation (if cultured in vitro, they would experience high levels of spontaneous apoptosis that would
prevent accurate measurement of anti-cancer drug- and peptide-induced death). T-ALL, T-acute lymphoblastic leukemia; AML, acute myeloid leukemia;
4-HC, 4-hydroperoxycyclophosphamide. * p<0.05 t-test after Bonferroni correction.
doi:10.1371/journal.pone.0120487.g002
TAT-RasGAP317-326 in Pediatric Tumors
PLOS ONE | DOI:10.1371/journal.pone.0120487 March 31, 2015 6 / 16
lymphoblastic leukemia (T-ALL) cell line (Fig 2A). Fig 2B shows the response of peripheral
blood lymphocytes (PBLs) derived from three different healthy subjects (subjects A-C) to the
RasGAP-derived peptide in combination or not with the genotoxins used in Fig 2A. The Ras-
GAP-derived peptide by itself did not display any toxicity toward the PBLs. The sensitivity of
the non-tumor lymphocytes for the tested chemotherapies alone was similar to the sensitivity
of the CCRF-CEM cell line (even slightly increased in the case of doxorubicin for the healthy
subjects A and C). The observation that cancer and normal lymphocytes were similarly sensi-
tive to genotoxins was somehow surprising because the rationale to use a given chemotherapy
is that it will target preferentially the malignant cells. Nevertheless, the important information
drawn from Fig 2B is that TAT-RasGAP317-326 does not sensitize PBLs to etoposide-, vincris-
tine- and doxorubicin-mediated death. The peptide however did sometimes sensitize PBLs to
4-HC (Fig 2B), suggesting that TAT-RasGAP317-326 can affect the viability of normal cells in
some treatment combinations.
TAT-RasGAP317-326 can potentiate genotoxin-induced cell death in
Ewing sarcoma
To extend the investigation on TAT-RasGAP317-326 in non-leukemia childhood cancer, the ef-
ficacy of TAT-RasGAP317-326 was also tested in Ewing sarcoma cells. The results show that the
RasGAP-derived peptide is also able to sensitize these cells to various genotoxins, although to a
lower extent than in leukemias (Fig 3). In some cases, no sensitization was observed (e.g. when
vincristine was used in the A673 and TC252 cell lines). Here again, TAT-RasGAP317-326 alone
did not display any toxicity toward the Ewing sarcoma cells (Fig 3).
Fig 3. TAT-RasGAP317-326 potentiates genotoxin-induced cell death in Ewing sarcoma. Three Ewing sarcoma cell lines (EW-11, A673 and TC252)
were seeded in 6-well plates and after 24 hours were treated with 4-HC, etoposide, vincristine, or doxorubicin at the indicated concentrations in the presence
or in the absence of 10 μM TAT-RasGAP317-326. One day later, cell death was evaluated. 4-HC, 4-hydroperoxycyclophosphamide. * p<0.05 t-test after
Bonferroni correction.
doi:10.1371/journal.pone.0120487.g003
TAT-RasGAP317-326 in Pediatric Tumors
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The NB1 neuroblastoma derived-cell lines are directly killed by
TAT-RasGAP317-326
Acquired chemoresistance is an important cause of failure of treatment of neuroblastoma. To
assess the effect of TAT-RasGAP317-326 in cells that were exposed to high doses of chemothera-
pies and therefore that potentially have acquired resistance to these cytotoxic agents, we select-
ed primary tumor cells of a single patient at different stages of the disease. The NB1 cells are
high risk stage 4 primary neuroblastoma cells derived from bone marrow samples that were es-
tablished at initial diagnosis (NB1-NBM and NB1-FBS) and at subsequent relapse after multi-
agent chemotherapy (NB1-FBS-Re) (Fig 4A). NB1-FBS and NB1-FBS-Re cell lines were cul-
tured in 10% fetal bovine serum (FBS)-containing DMEMmedium, while NB1-NBM cells
were established in neural basic medium (NBM). NBM is a stem cell permissive serum-free,
bFGF-, EGF- and B27-supplemented medium to support the growth of neural crest cells, the
tissue of origin of neuroblastoma [38, 39].
Fig 4A shows that the NB1-NBM and NB1-FBS cell lines do not display the same sensitivity
toward the tested chemotherapies. Moreover, the efficacy of TAT-RasGAP317-326 to improve
the killing efficiency of 4-HC varies between these two cell lines: the NB1-FBS cells were found
to be very sensitive to the sensitization effect of the peptide, while the NB1-NBM cells were not
affected by the presence of TAT-RasGAP317-326. As the only difference between the NB1-NBM
and NB1-FBS cell lines is the medium in which they are cultured, one could hypothesize that
the metabolism of the NB1 cells varies from one culture condition to the other and that this dif-
ferentially modulates the sensitivity of the tumor cells to TAT-RasGAP317-326.
To investigate whether the sensitization effect of TAT-RasGAP317-326 was still efficient on
relapsed neuroblastoma cells, we compared its efficacy between the NB1-FBS cells and the
NB1-FBS-Re cells. Both cell lines are cultured in the same culture medium. The treatment regi-
men that was used to treat the patient is illustrated in Fig 4A. The patient, the relapsed cells of
which were derived, was exposed to the four drugs (4-HC, etoposide, vincristine and doxorubi-
cin) tested in this study. However, except for the 4-HC-treated conditions where we can ob-
serve a slight resistance to this drug in the NB1-FBS-Re cells, the relapsed cells are not more
resistant to etoposide, vincristine and doxorubicin than the cells derived from initial diagnosis
(Fig 4A). On the contrary, NB1-FBS-Re cells show an increased sensitivity to doxorubicin com-
pared to the NB1-FBS cells. Nevertheless, TAT-RasGAP317-326 sensitizes the three primary
NB1-derived cell lines, although to a different level of efficacy according to the cell line and the
tested chemotherapy (Fig 4A).
In most cases, TAT-RasGAP317-326 does not induce tumor cell death by itself. However, we
found out that the three NB1 derived-cell lines can be directly killed by the RasGAP-derived
peptide (Fig 4A). The dose needed to induce cell death (20 μM) is nevertheless higher than the
dose used to sensitize the cells to genotoxins (10 μM).
To complete the investigation of the effect of TAT-RasGAP317-326 in neuroblastoma tumor
type, we also tested the peptide on LAN-1, another neuroblastoma cell line derived from an ag-
gressive stage 4 neuroblastoma. Fig 4B shows that the RasGAP-derived peptide displays a slight
sensitization effect toward this cell line. Unlike the NB1 derived-cell lines, TAT-RasGAP317-326
alone was not able to kill LAN-1 cells (Fig 4B), meaning that TAT-RasGAP317-326-induced cell
death is not a specificity shared by all neuroblastomas.
The sensitizing activity of TAT-RasGAP317-326 is carried by the RasGAP-
derived sequence
To assess the specificity of the chemo-sensitizing activity of TAT-RasGAP317-326, three differ-
ent control peptides were tested: a peptide composed of the TAT sequence only (TAT), a
TAT-RasGAP317-326 in Pediatric Tumors
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Fig 4. TAT-RasGAP317-326 sensitizes neuroblastoma cells to chemotherapy and displays a direct killing effect on NB1-derived cell lines. A. The light
grey thick arrow on top of the figure represents the treatment regimen administrated to the patient from whom the three NB1-derived cell lines were
established. The NB1 cells are derived from primary high risk neuroblastoma bone marrow samples. NB1-NBM and NB1-FBS were established at initial
diagnosis and cultured in NBM and DMEMmedia, respectively. NB1-NBM-Re was established at a subsequent relapse and cultured in DMEM. The three
NB1-derived cell lines were treated as described in Fig 3. B. The LAN-1 cell line is derived from a high risk neuroblastoma. LAN-1 cells were treated as
described in Fig 3. M, month; BM, bone marrow; 4-HC, 4-hydroperoxycyclophosphamide. * p<0.05 t-test after Bonferroni correction.
doi:10.1371/journal.pone.0120487.g004
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peptide in which the RasGAP sequence was scrambled (TAT-Scrambled), and a peptide in
which the first tryptophan of the RasGAP sequence was substituted into an alanine residue
(TAT-Mutated). This tryptophan was recently shown to be essential for the sensitizing activity
of TAT-RasGAP317-326 in adult tumors [16]. The effect of TAT-RasGAP317-326 and the three
control peptides was tested in CCRF-CEM cells in combination with various anti-cancer drugs
at doses that allowed the greatest sensitization activity to be detected. CCRF-CEM cells were
used because this leukemia cell line was the one most efficiently sensitized by the RasGAP-de-
rived peptide. Fig 5A shows that all three control peptides had a tendency to slightly favor the
death of CCRF-CEM cells when combined with the different anti-cancer drugs but in most
cases this did not reach statistical significance. In contrast, TAT-RasGAP317-326 markedly, and
always significantly, sensitized these cells to the drugs. The slight sensitization effect of the con-
trol peptides is most likely due to the cell penetrating activity of the TAT moiety, which has the
potential to negatively affect cellular homeostasis [40]. Similar results were obtained when the
TC252 Ewing sarcoma cell line and the NB1-FBS neuroblastoma cell line were used: TAT-Ras-
GAP317-326 significantly increased their sensitivity to 4-HC, while the three control peptides
did not, or only minimally (Fig 5B and 5C). These data indicate that the tumor sensitizing ac-
tivity of TAT-RasGAP317-326 only marginally relies on its ability to penetrate cells via the TAT
cell-permeable sequence. Therefore, it can be concluded that the sensitizing activity of
TAT-RasGAP317-326 is mainly carried by the RasGAP-derived sequence.
Discussion
The currently applied therapies to treat childhood solid cancers, such as neuroblastoma and
Ewing sarcoma, need to be more efficient and specific to improve clinical outcome. Leukemia
has usually a better 5-year survival rate than pediatric solid tumors, but long-term effects of the
therapy remain an important cause of morbidity and mortality. Furthermore, acquired resis-
tance to the conventional treatments is responsible for relapses and poor outcome. According-
ly, finding less toxic and more efficient therapeutic agents to treat pediatric cancers is a
necessity to decrease drug-induced deleterious side effects and the associated mortality [3].
In the present study, we assessed the effect of TAT-RasGAP317-326 in several childhood can-
cer cell lines. This RasGAP-derived peptide was already known to sensitize adult tumor cells in
vitro and in vivo to various anti-cancer therapies [12]. Our results show that TAT-RasGAP317-
326 significantly sensitizes childhood cancer cells in the majority of the tested conditions. How-
ever, in some cases, tumor cells did not, or minimally, respond to the peptide. The pediatric
tumor-sensitizing effect illustrated in this study was reached using half of the peptide concen-
tration used previously to sensitize adult cancer cells (10 μMTAT-RasGAP317-326 in this study
instead of 20 μM in the paper of Michod et al. [12]). Possibly, the dose of TAT-RasGAP317-326
could be doubled to increase the sensitizing efficacy of the peptide in the conditions where it
was less efficient. Since primary tumor cells represent a more clinically relevant condition, we
also tested the peptide in primary neuroblastoma cells derived from bone marrow samples
from a single patient (the three NB1-derived cell lines showed in Fig 4). The results show that
the RasGAP-derived peptide sensitizes primary tumor cells, suggesting that it could exert its
anti-cancer activity on tumors in an in vivo context.
The mechanism of action of TAT-RasGAP317-326 remains to be precisely determined [18–
20]. We initially assumed that working with a large panel of cell lines and cytotoxic agents
would allow us to draw a pattern that could be used to predict which type of childhood tumors
display sensitivity to TAT-RasGAP317-326 in response to a given drug. Such information would
be helpful to decipher the mode of action of TAT-RasGAP317-326. For this purpose, we analyzed
how the half maximal inhibitory concentration (IC50) for each chemotherapeutic agent was
TAT-RasGAP317-326 in Pediatric Tumors
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modified by the presence of TAT-RasGAP317-326 for a given cell line (Table 2). The RasGAP-
derived peptide decreased the IC50 for most genotoxins in most cell lines. However, no specific
pattern based on tumor origin or drug type could be deduced from the data presented in
Table 2. We also looked whether there were some common specific mutations in well-known
oncogenes or tumor suppressor genes (e.g. HRAS, KRAS, NRAS, HDM2, N-MYC, C-MYC,
TAL1, FLI-1, MLL, p53 and Rb1) in the analyzed cell lines. Again, no association could be
Fig 5. The RasGAPmoiety carries the tumor sensitizing activity of TAT-RasGAP317-326. A. CCRF-CEM cells were seeded in 6-well plates and directly
treated with 10 μM TAT-RasGAP317-326, TAT, TAT-Scrambled or TAT-Mutated in the absence or in the presence of 4-HC, etoposide, vincristine or
doxorubicin at the indicated concentrations. After 24 hours of drug incubation, 7-AAD or Annexin V-FITC staining was performed to evaluate cell death.B-C.
The TC252 (B) and NB1-FBS (C) cell lines were treated similarly but in combination with 4-HC only. P10, TAT-RasGAP317-326; TAT-S, TAT-Scrambled;
TAT-M, TAT-Mutated; 4-HC, 4-hydroperoxycyclophosphamide. Means with the same letter are not significantly different.
doi:10.1371/journal.pone.0120487.g005
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Table 2. Sensitizing effect of the TAT-RasGAP317-326 toward childhood tumors.
Cell line Tumor type Chemotherapy IC50 (without peptide) IC50 (with 10 μM
TAT-RasGAP317-326)
Effect of TAT-
RasGAP317-326 on IC50
THP-1 AML 4-HC [μM] 38 25 Decrease
Etoposide [μg/ml] >20 10 Decrease
Vincristine [μM] >10 >10 -
Doxorubicin [μg/ml] 0.3 0.3 No change
M-07e AML 4-HC [μM] 20 11 Decrease
Etoposide [μg/ml] >150 150 Decrease
Vincristine [μM] >10 1 Decrease
Doxorubicin [μg/ml] 2 2 No change
CEM T-ALL 4-HC [μM] 25 12.5 Decrease
Etoposide [μg/ml] >100 25 Decrease
Vincristine [μM] >10 >10 -
Doxorubicin [μg/ml] >10 >10 -
EW-11 Ewing sarcoma 4-HC [μM] 40 35 Decrease
Etoposide [μg/ml] >200 >200 -
Vincristine [μM] >10 >10 -
Doxorubicin [μg/ml] 3 1 Decrease
A673 Ewing sarcoma 4-HC [μM] 20 10 Decrease
Etoposide [μg/ml] >200 >200 -
Vincristine [μM] >10 >10 -
Doxorubicin [μg/ml] 2 0.4 Decrease
TC252 Ewing sarcoma 4-HC [μM] 27 10 Decrease
Etoposide [μg/ml] >200 25 Decrease
Vincristine [μM] >10 >10 -
Doxorubicin [μg/ml] >10 3 Decrease
NB1-NBM Neuroblastoma 4-HC [μM] 27 27 No change
Etoposide [μg/ml] 25 1 Decrease
Vincristine [μM] 10 0.04 Decrease
Doxorubicin [μg/ml] 0.3 0.07 Decrease
NB1-FBS Neuroblastoma 4-HC [μM] 10 3 Decrease
Etoposide [μg/ml] 2.5 1 Decrease
Vincristine [μM] >10 >10 -
Doxorubicin [μg/ml] >10 >10 -
NB1-FBS-Re Neuroblastoma 4-HC [μM] 15 2.5 Decrease
Etoposide [μg/ml] 2.5 1 Decrease
Vincristine [μM] >10 >10 -
Doxorubicin [μg/ml] 0.05 0.004 Decrease
LAN-1 Neuroblastoma 4-HC [μM] 26 24 Decrease
Etoposide [μg/ml] 200 50 Decrease
Vincristine [μM] 0.1 0.02 Decrease
Doxorubicin [μg/ml] 0.3 0.3 No change
This table summarizes the effect of TAT-RasGAP317-326 in combination with 4-HC, etoposide, vincristine or doxorubicin on the IC50 of the cell lines studied
in this paper. IC50 were calculated for each chemotherapeutic agent in the absence or in the presence of 10 μM TAT-RasGAP317-326. AML, acute myeloid
leukemia; T-ALL, T-acute lymphoblastic leukemia; 4-HC, 4-hydroperoxycyclophophamide.
doi:10.1371/journal.pone.0120487.t002
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found between the presence of specific mutations in a cancer cell line and its ability to be sensi-
tized by the RasGAP-derived peptide.
An interesting aspect of this research is that the sensitization effect of TAT-RasGAP317-326
can be differentially modulated by the cell culture conditions. This feature is illustrated by the
fact that the NB1-FBS cells, but not the NB1-NBM cells, are sensitive to the effect of the peptide.
These two cell lines are derived from the same neuroblastoma tumor at initial diagnosis (see Fig
4) but they were cultured in different media. These two cell lines appear to have the same geno-
mic alterations. Indeed, they possess identical array-CGH profiles with the same typical neuro-
blastoma-associated segmental chromosomic alterations (unpublished data). So if these two cell
lines have identical array-CGH profiles, what could explain their different sensitivity to
TAT-RasGAP317-326? One possibility is that the medium in which they are grown modulate
their metabolism differentially. This might in turn affect their sensitivity to anti-cancer treat-
ments. There are indeed accumulating evidence that the metabolic state of cancer cells play an
important role in the way they respond to anti-cancer drugs [41]. Another hypothesis is that
different cell populations are selected upon passages in different medium. Unlike the FBS-con-
taining DMEMmedium, the NBMmedium blocks cell differentiation. Consequently, the
NB1-FBS cells are potentially more differentiated than the NB1-NBM cells. The state of differ-
entiation of the cells could explain their different behavior in response to TAT-RasGAP317-326.
Alternatively, passage in different medium may induce differential epigenetic modifications or
mutations that impact on the sensitivities of the NB1-FBS and NB1-NBM cell lines toward the
RasGAP-derived peptide.
We have previously shown that the genotoxin sensitivity of non-tumor cells is not affected
by TAT-RasGAP317-326 [12]. Moreover, doses that induce tumor sensitization in vivo do not
exert any detectable toxic side effects [13]. In the present study, we tested the effect of the pep-
tide in isolated lymphocytes from blood of healthy patients. We confirmed the non-toxic effect
of the RasGAP-derived peptide in these cells. The peptide was also unable to sensitize the iso-
lated lymphocytes to etoposide, vincristine or doxorubicin. However, TAT-RasGAP317-326 was
found sometimes to sensitize non-malignant lymphocytes to 4-HC-induced death. This finding
is clinically relevant because one of the most frequent dose-limiting side effect of chemotherapy
is hematological toxicity [42]. Consequently, if TAT-RasGAP317-326 increases genotoxin-in-
duced side effects toward non-tumor cells, it would lose its attractivity as an anti-cancer candi-
date to treat childhood tumors. However, cyclophosphamide (and consequently its active form
4-HC) possesses hematologic toxic effects. This toxicity depends of the cellular expression level
of aldehyde dehydrogenase (ALDH), an enzyme responsible for cyclophosphamide detoxifica-
tion. The expression level of ALDH is very low in mature hematopoietic cells such as lympho-
cytes, while in hematopoietic stem cells, ALDH is expressed at high levels. Thus, the later are
relatively resistant to cyclophosphamide, whereas this alkylating agent is toxic toward mature
lymphocytes [43]. This feature explains why white blood cell counts drop in patients treated
with cyclophosphamide [44]. However this drop is transient and a rapid hematologic recovery
invariably occurs after cyclophosphamide therapy. Consequently, the observed sensitizing ef-
fect of TAT-RasGAP317-326 in combination with 4-HC in healthy lymphocytes may not be clin-
ically incompatible, provided that the negative effect of the peptide is limited to mature
hematopoietic cells and does not affect hematopoietic stem cells.
Although in most cases TAT-RasGAP317-326 by itself does not kill tumor cells, we found out
that it induced the cell death of the three NB1-derived cell lines tested here. This newly discov-
ered feature has two consequences. First, it will give us the opportunity to study the pro-death
activity of the peptide alone. This possibly may facilitate deciphering its mode of action by, for
example, using genome-scale knockout screenings [45, 46]. Second, it indicates that the Ras-
GAP-derived peptide, in its own right, corresponds to a new cytotoxic agent in certain tumors.
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In conclusion, our work shows that in most cases TAT-RasGAP317-326 sensitizes childhood
cancer cells to genotoxins. However, it was not possible to predict the efficacy of this sensitiza-
tion based on the tumor type and the drug used. Additional investigation is therefore required
to increase our understanding on how TAT-RasGAP317-326 works and to determine the indica-
tions for which it might be useful in the clinic.
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